Vitae Biomedical Co., Ltd. is a Taiwan-based precision diagnostics company focused on the development of non-invasive urine-based technologies for lung cancer risk assessment.

Through ELISA-based biomarker analysis, Vitae Biomedical provides accessible and low-burden testing solutions designed to support clinical risk assessment, health management, and healthcare workflow integration. The company is committed to advancing practical diagnostic approaches that enable earlier risk identification and improve clinical decision support in lung cancer care.

Vitae Biomedical has established a stable clinical testing service model in Taiwan, accumulating more than 50,000 clinical data records through collaborations with over 600 clinics and healthcare institutions.

Building upon this clinical and operational foundation, the company continues to strengthen its real-world implementation capabilities while expanding opportunities for international collaboration and market development.

The company’s core technology platform is based on urine-derived biomarker analysis for lung cancer risk assessment.

Vitae Biomedical is actively advancing:

   •    ELISA-based diagnostic applications

   •    Lung cancer-related biomarker analysis (GM2AP)

   •    Non-invasive testing technologies

   •    Biosensor platform development

   •    POCT (Point-of-Care Testing) solutions

These technologies are designed to support broader accessibility, scalability, and future integration into clinical and healthcare systems.

Vitae Biomedical’s technologies are intended to support:

   •    Lung cancer risk stratification

   •    Clinical risk assessment workflows

   •    Health management applications

   •    Imaging follow-up and patient management

By providing additional risk assessment information before and after imaging examinations, the company aims to support more efficient clinical workflows and healthcare resource utilization.

With CE-IVD certification and an established clinical deployment foundation in Taiwan, Vitae Biomedical is actively expanding international partnerships and market opportunities across Europe and Asia.

The company is committed to building long-term collaborations with healthcare institutions, industry partners, and clinical organizations to advance non-invasive diagnostic applications and healthcare accessibility worldwide.